Table Graph
      published meta-analysis   sensitivity analysis   studies

colchicine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsCOLCHIVID, 2021 0.83 [0.35; 1.95] 0.83[0.35; 1.95]COLCHIVID, 202110%NAnot evaluable deathsdetailed resultsCOLCHIVID, 2021 0.69 [0.20; 2.40] Lopes MIF, 2020 1.06 [0.02; 56.61] Salehzadeh, 2020 1.00 [0.02; 51.41] 0.74[0.24; 2.31]COLCHIVID, 2021, Lopes MIF, 2020, Salehzadeh, 202030%261NAnot evaluable hospital dischargedetailed resultsCOLCHIVID, 2021 1.13 [0.76; 1.67] 1.13[0.76; 1.67]COLCHIVID, 202110%126NAnot evaluable ICU admissiondetailed resultsLopes MIF, 2020 1.06 [0.06; 18.45] 1.06[0.06; 18.45]Lopes MIF, 202010%35NAnot evaluable adverse eventsdetailed resultsCOLCHIVID, 2021 1.63 [0.67; 3.95] 1.63[0.67; 3.95]COLCHIVID, 202110%NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-01 19:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 560,1102 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons